NCAPG Antibody

What is NCAPG and what cellular functions does it perform?

NCAPG functions as a regulatory subunit of the condensin complex, which is essential for the conversion of interphase chromatin into mitotic-like condensed chromosomes. The condensin complex introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases .

As a key component in chromosome organization during cell division, NCAPG plays crucial roles in:

• Mitotic chromosome architecture establishment

• Physical rigidity maintenance of the chromatid axis

• Cell cycle regulation, particularly during mitosis

• Genomic stability preservation

What applications are NCAPG antibodies typically used for in research?

NCAPG antibodies can be utilized across multiple experimental applications, with varying levels of validation:

When selecting an antibody for your experiments, verify that it has been validated for your specific application of interest and target species.

How should NCAPG antibodies be stored and handled for optimal performance?

For maximum antibody stability and performance:

• Store at -20°C for long-term storage (stable for approximately one year after shipment)

• For frequent use, store at 4°C for up to one month to minimize freeze-thaw cycles

• Most commercial NCAPG antibodies are supplied in PBS containing preservatives such as sodium azide (0.02%) and stabilizers like glycerol (50%)

• While some manufacturers suggest aliquoting is unnecessary for -20°C storage, dividing into single-use aliquots is recommended if repeated freeze-thaw cycles are anticipated

• Allow antibodies to completely thaw and equilibrate to room temperature before opening vials

What are the recommended controls when validating NCAPG expression in cancer tissues?

A comprehensive validation strategy should include:

• Positive controls: Include known NCAPG-expressing cell lines (HEK-293, HeLa, HepG2)

• Negative controls:

  • Primary antibody omission

  • IgG isotype control

  • NCAPG-knockdown cells (using siRNA or CRISPR-Cas9)

• Adjacent normal tissue: Always compare tumor samples with matched adjacent normal tissue from the same patient

• Antibody validation: If possible, validate findings with at least two different NCAPG antibodies targeting different epitopes

• Technical replicates: Perform at least three independent experiments

Multiple studies have demonstrated that comparison between tumor tissue and adjacent normal tissue is critical for accurate evaluation of NCAPG overexpression .

How can researchers optimize Western blot protocols for detecting NCAPG?

NCAPG detection by Western blot requires specific optimization:

• Sample preparation: Use fresh tissue samples or freshly cultured cells whenever possible. Extract proteins using RIPA buffer supplemented with protease inhibitors.

• Gel selection: Use 5% SDS-PAGE gel as NCAPG is a high molecular weight protein (approximately 114-131 kDa) .

• Transfer conditions: For large proteins like NCAPG:

  • Extended transfer time (2+ hours)

  • Lower voltage transfer

  • Use PVDF membrane rather than nitrocellulose

  • Add 0.1% SDS to the transfer buffer to facilitate large protein transfer

• Blocking: 5% non-fat dry milk in TBST for 1-2 hours at room temperature

• Antibody incubation:

  • Primary antibody: 1:2000 dilution in 5% BSA overnight at 4°C

  • Secondary antibody: 1:5000 anti-rabbit HRP conjugate for 1 hour at room temperature

• Expected band size: NCAPG appears at 114-131 kDa

What are the mechanistic roles of NCAPG in cancer progression across different tumor types?

NCAPG has emerged as a pan-cancer oncogene with multiple mechanisms identified across tumor types:

Importantly, multivariate analyses have demonstrated that NCAPG expression is an independent risk factor for mortality in hepatocellular carcinoma patients, together with TNM staging and Barcelona Clinic Liver Cancer (BCLC) staging .

How can researchers effectively validate NCAPG knockdown experiments when studying its function?

When conducting NCAPG knockdown experiments, implement these validation measures:

• Multiple siRNA sequences: Use at least two different siRNA sequences targeting different regions of NCAPG mRNA to rule out off-target effects.

• Expression validation: Confirm knockdown at both:

  • mRNA level using qRT-PCR

  • Protein level using Western blot

• Rescue experiments: Perform rescue experiments by re-expressing siRNA-resistant NCAPG to confirm observed phenotypes are due to specific NCAPG depletion.

• Knockdown efficiency quantification: Quantify knockdown efficiency; aim for >70% reduction.

• Time-course analysis: Assess phenotypes at multiple time points as NCAPG has cell cycle-dependent effects.

For example, in a breast cancer study, researchers verified siRNA knockdown efficiency using qPCR, demonstrating significantly decreased NCAPG expression with siNCAPG1 and siNCAPG2, then confirmed functional effects through colony formation assays, EdU proliferation assays, and protein expression of downstream targets .

What are the potential pitfalls in interpreting immunohistochemistry results for NCAPG in tumor samples?

Several challenges can confound NCAPG IHC interpretation:

• Heterogeneous expression: NCAPG may show heterogeneous expression within different regions of the same tumor. Evaluating multiple fields (at least 5) is recommended.

• Cell cycle-dependent expression: As a cell cycle regulator, NCAPG expression varies depending on cell cycle phase. This can affect staining patterns in asynchronous tumor cell populations.

• Subcellular localization: NCAPG shows both cytoplasmic and nuclear staining patterns with varying intensities . Be consistent in scoring methodology:

  • Document both staining intensity (0-3+) and percentage of positive cells

  • Consider separate scores for nuclear and cytoplasmic staining

• Antibody specificity: Confirm antibody specificity through knockout/knockdown validation. Several commercial antibodies show cross-reactivity with NCAPG2 .

• Threshold determination: Use X-tile software or similar statistical methods to determine the optimal cut-off values for high vs. low expression when correlating with clinical outcomes .

How does NCAPG expression correlate with patient prognosis across different cancer types?

Multiple studies demonstrate NCAPG as a prognostic marker across cancer types:

Multivariate Cox regression analysis confirms NCAPG as an independent prognostic factor, even after adjusting for established clinical parameters such as TNM staging .

What are the current challenges in targeting NCAPG for cancer therapy?

Despite its promise as a therapeutic target, several challenges exist:

• Essential cellular function: As NCAPG is critical for chromosome condensation and cell division, complete inhibition may affect normal cellular functions, potentially causing significant side effects.

• Structural complexity: NCAPG's large size (114 kDa) and complex protein-protein interactions make it challenging to develop small molecule inhibitors.

• Context-dependent mechanisms: NCAPG acts through different pathways in different cancer types (Wnt/β-catenin in colorectal cancer, PI3K/AKT in HCC and cardia adenocarcinoma), complicating a one-size-fits-all therapeutic approach .

• Compensatory mechanisms: Preliminary research suggests potential compensatory upregulation of related condensin complex members when NCAPG is inhibited.

• Delivery methods: For RNA interference or CRISPR-based therapies targeting NCAPG, tumor-specific delivery remains challenging.

Recent advances in CRISPR-Cas9 genome editing provide promising avenues, as NCAPG has been identified as a true target for HCC tumor cell growth inhibition .

How can researchers address non-specific binding when using NCAPG antibodies?

When facing non-specific binding with NCAPG antibodies:

• Antibody validation: Verify antibody specificity using positive controls (HEK-293, HeLa cells) and negative controls (NCAPG-knockdown cells) .

• Blocking optimization:

  • For Western blot: Try different blocking agents (5% milk, 5% BSA, commercial blockers)

  • For IHC/IF: Consider extending blocking time (2+ hours) or using commercial blockers containing both proteins and detergents

• Antibody dilution: Test a dilution series. For Western blot, recommended dilutions range from 1:500 to 1:50000, depending on the specific antibody .

• Incubation conditions: Optimize temperature and duration for primary antibody incubation:

  • 4°C overnight generally provides better specificity than room temperature incubation

  • For problematic antibodies, try 48-hour incubation at 4°C with more dilute antibody

• Wash stringency: Increase washing steps duration and number (5x5 minutes with TBST/PBST)

• Cross-adsorption: If species cross-reactivity is an issue, use cross-adsorbed secondary antibodies

How do researchers distinguish between NCAPG and its paralog NCAPG2 in experimental settings?

Distinguishing between these related proteins requires careful experimental design:

• Antibody selection: Choose antibodies raised against non-conserved regions. NCAPG and NCAPG2 share structural similarity but have distinct sequences:

  • NCAPG: 1015 amino acids, 114 kDa

  • NCAPG2: associated with condensin-2 complex

• Western blot identification:

  • NCAPG typically appears at 114-131 kDa

  • NCAPG2 has a predicted molecular weight of 131 kDa

  • Use positive controls with known expression of each protein

• qRT-PCR primers: Design primers targeting unique regions of each transcript:

  • Validate primer specificity using overexpression constructs

  • Include melt curve analysis to confirm amplification of a single product

• siRNA specificity: When performing knockdown experiments, design siRNAs targeting unique regions and validate specificity by measuring both NCAPG and NCAPG2 expression.

• Functional distinction: While both proteins are involved in chromosome condensation, they participate in different complexes:

  • NCAPG: condensin I complex

  • NCAPG2: condensin II complex

Understanding their distinct roles is important as NCAPG2 has also been identified as an immunological and prognostic biomarker in cancers .

How is NCAPG being investigated as an immunotherapy biomarker in cancer research?

Recent research has revealed important connections between NCAPG and tumor immunity:

• Immune checkpoint correlation: NCAPG expression shows significant correlations with immune checkpoint genes, suggesting potential roles in immunotherapy response prediction .

• Tumor immune infiltration: Pan-cancer analyses reveal associations between NCAPG expression and immune cell infiltration scores, with specific patterns varying by cancer type .

• Biomarkers of immunotherapy response: NCAPG is being evaluated alongside established immunotherapy biomarkers:

  • Tumor Mutational Burden (TMB)

  • Microsatellite Instability (MSI)

  • Tumor stemness scores

• Immunologic targeting potential: As NCAPG is overexpressed in multiple cancer types but has limited expression in normal tissues, it represents a potential target for immunotherapeutic approaches, including:

  • Cancer vaccines

  • Chimeric antigen receptor (CAR) T-cell therapy

  • Bispecific antibodies

A comprehensive study across cancer types demonstrated that NCAPG could potentially guide immunotherapy decisions, providing new insights into precision medicine approaches .

What are the latest methodological advances in studying NCAPG's interaction with the condensin complex?

Recent methodological innovations have enhanced our understanding of NCAPG's role in the condensin complex:

• Immunoprecipitation-Mass Spectrometry (IP-MS): This technique has been crucial for identifying NCAPG's protein interaction network. For example, researchers used IP-MS to discover interactions between NCAPG and CKII proteins in hepatocellular carcinoma .

• Proteomic sequencing: This approach revealed a close association between NCAPG and CKII, with their interaction confirmed by Co-immunoprecipitation (CO-IP) .

• Proximity labeling approaches: BioID and APEX2 methods are being applied to map spatial protein interactions of condensin complex members in living cells.

• Chromatin immunoprecipitation sequencing (ChIP-seq): This technique helps identify genomic binding sites of NCAPG, revealing its distribution patterns along chromosomes.

• Live-cell imaging: Advanced microscopy techniques combined with fluorescently tagged NCAPG provide insights into its dynamic behavior during different cell cycle phases.

• Cryo-electron microscopy: Recent structural studies are beginning to reveal the molecular architecture of condensin complexes, including NCAPG's position and contributions to complex assembly.

These methodologies have collectively advanced our understanding of how NCAPG contributes to chromosome architecture and cancer progression through both condensin-dependent and independent mechanisms.

What databases and bioinformatic tools are most valuable for NCAPG expression analysis in cancer research?

Researchers studying NCAPG can leverage several key resources:

When using these tools, researchers should note that optimal cut-off values for high vs. low NCAPG expression can be determined using X-tile software, as demonstrated in studies correlating NCAPG expression with clinical features .

What are the recommended experimental models for studying NCAPG function in cancer?

Multiple experimental models offer distinct advantages for NCAPG research:

In vitro models:

• Cell lines: Validated NCAPG-expressing cell lines include:

  • HCC: HepG2

  • Breast cancer: MDA-MB-231

  • Cervical cancer: HeLa

  • Kidney: HEK-293

  • Cardia adenocarcinoma: SGC-7901, AGS

• 3D organoid cultures: Emerging as more physiologically relevant models that maintain tissue architecture and heterogeneity

In vivo models:

• Xenograft models: BALB/c-nu/nu mice have been successfully used for in vivo NCAPG function studies

• Genetic mouse models: Conditional NCAPG knockout models are being developed

Genetic manipulation approaches:

• siRNA: Effective for transient NCAPG knockdown. Use at least two different siRNA sequences (siNCAPG1, siNCAPG2) to confirm specificity

• shRNA: Provides longer-term knockdown for extended studies

• CRISPR-Cas9: Enables complete knockout or targeted mutations. NCAPG has been identified as a true target by CRISPR screens for HCC tumor cell growth

• Overexpression systems: Useful for gain-of-function studies using vectors containing NCAPG cDNA